A Drug Master File isn't a clean bill of health
An active US Type II Drug Master File is the filing an API maker holds to supply the regulated US market — and it is often read as a mark of quality. It is not. Across 1,802 companies holding an active Type II DMF, at least 1 in 8 also carries an FDA enforcement action on record. A DMF documents a process to the agency; it does not certify the site is in good standing today.
Data as of August 2026· Sources: FDA List of Drug Master Files & FDA enforcement records · Analysis by PharmaTek Intelligence
Key findings
A drug master file is not an FDA approval — and 221 holders show why
Of the 1,802 companies holding an active Type II DMF, 221 (about 12%) also have at least one FDA enforcement action on record — a Form 483, a Warning Letter, or a recall. The FDA reviews a DMF only inside a referencing NDA or ANDA, so a DMF on file means the process is documented, not that the site is currently in good standing. Read as a clearance, it misleads.
For 84 of those holders, it is more than one flag
84 of the 221 flagged holders — roughly two in five — carry two or more enforcement types: a Form 483 and a Warning Letter, or a recall on top. In supplier diligence the pattern matters more than any single event, and multi-type histories are the ones to weigh hardest. The breakdown: 148 holders with a 483, 122 with a Warning Letter, 66 with a recall.
Two countries hold the majority of US drug master files
Of the 1,488 holders with a known headquarters, China (33%) and India (21%) together account for 54%; the US is third at 13%. This is the filing base by company — a complement to where the plants physically sit — and it means the compliance question is concentrated in the same places as the supply.
Active Type II DMF holders by country
Top 12 countries by number of companies holding an active US Type II Drug Master File (1,488 of 1,802 holders have a confirmed HQ country).
Highlighted: China (largest) and India. Country is the holder's headquarters, not the site of manufacture.
What this means for sourcing teams
The headline is a correction of a common assumption. A DMF is a supply credential— evidence that a manufacturer has documented its process to the FDA and can support a customer's US filing. It is not a quality verdict, and treating it as one is how a supplier with an open compliance problem ends up on an approved-vendor list. For how to read the filing itself, see our guide to reading a supplier's DMF status.
The actionable finding is that a DMF and the inspection record are separate signals that must be read together. At least one in eight holders carries an enforcement action, and because our matching is deliberately conservative, the real figure is higher. Before you rely on a DMF, check the site's Form 483 and Warning Letter history — the process covered in our API supplier qualification checklist.
Concentration compounds the point. With more than half of all holders based in just two countries, the compliance question and the second-source question land in the same place: the realistic alternatives to a flagged supplier often sit in the same industrial cluster. That makes knowing your second source before you need it a materially different exercise from assuming one exists.
PharmaTek links every DMF in this analysis to its holder's company profile and its FDA enforcement record, so “do they hold a DMF” and “what is their compliance history” are answerable in one place rather than across separate FDA systems. See the supplier directory.
Methodology & sources
- Base: 1,802companies that PharmaTek resolves to a holder on the FDA “List of Drug Master Files” with an active Type II filing — 15,541 filings covering 8,208 distinct substances, as of August 2026. Holders on the FDA list that we could not confidently resolve to a company profile are excluded, so the true holder count is higher.
- Enforcement: a holder is counted if at least one FDA Form 483, Warning Letter, or recall is matched to the same company. Matching is by company identity and is deliberately conservative, so it under-counts — the 221 figure (about 12%) is a floor, not a ceiling.
- Geography: country is the holder company's headquarters, not the site of manufacture. 314 holders (17%) have no confirmed HQ country and are excluded from the country percentages.
- A Drug Master File is a confidential submission the FDA reviews only in the context of a referencing application; it is not itself an approval or a certificate of GMP compliance.
Cite this report:PharmaTek Intelligence, “A Drug Master File Isn't a Clean Bill of Health,” August 2026. https://pharmatek.co.uk/reports/drug-master-file-enforcement
This report describes the holder base in aggregate. Enforcement records reflect a point in time and a specific facility, are frequently resolved, and this analysis makes no judgement about any individual company. Always confirm against primary FDA sources before a sourcing decision.
Screen DMF holders against their FDA record
Search active Type II DMF holders alongside their Form 483, Warning Letter and recall history — the filing and the inspection record in one place.
Explore the directory